GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » Cash Ratio

Rhythm Biosciences (ASX:RHY) Cash Ratio

: 1.86 (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Rhythm Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 was 1.86.

Rhythm Biosciences has a Cash Ratio of 1.86. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Rhythm Biosciences's Cash Ratio or its related term are showing as below:

ASX:RHY' s Cash Ratio Range Over the Past 10 Years
Min: 1.69   Med: 7.82   Max: 73.89
Current: 1.86

During the past 6 years, Rhythm Biosciences's highest Cash Ratio was 73.89. The lowest was 1.69. And the median was 7.82.

ASX:RHY's Cash Ratio is ranked better than
65.24% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05 vs ASX:RHY: 1.86

Rhythm Biosciences Cash Ratio Historical Data

The historical data trend for Rhythm Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Premium Member Only 12.80 2.32 1.69 8.15 2.36

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.49 8.15 7.82 2.36 1.86

Competitive Comparison

For the Diagnostics & Research subindustry, Rhythm Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences Cash Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Cash Ratio falls into.



Rhythm Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Rhythm Biosciences's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=4.169/1.766
=2.36

Rhythm Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.263/0.679
=1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (ASX:RHY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Rhythm Biosciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (ASX:RHY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (ASX:RHY) Headlines

No Headlines